Education
About Us
Working with TipRanks
Follow Us
Eyepoint Pharma (EYPT)
:EYPT
EYPT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.91 - $14.42
Previous CloseN/A
Volume354.62K
Average Volume (3M)773.38K
Market Cap
$920.18M
Enterprise Value$424.09M
Total Cash (Recent Filing)$318.19M
Total Debt (Recent Filing)$24.08M
Price to Earnings (P/E)―
Beta2.30
Next Earnings
Oct 29, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.85
Shares Outstanding68,927,420
10 Day Avg. Volume913,751
30 Day Avg. Volume773,375
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.46
Enterprise Value/Revenue7.57
Enterprise Value/Gross Profit8.11
Enterprise Value/Ebitda-2.85
Forecast
1Y Price Target
$33.00Price Target Upside147.19% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe rapid pace of enrollment completion for both LUGANO and LUCIA signifies enthusiasm among the wet AMD community for a treatment option with 6-month redosing.
Market PositionEyePoint could be the first long-acting TKI to market with the critical Q6M label.
Product DevelopmentEYPT has a more robust set of P2 data to support the potential of Duravyu.
Bears Say
Market RisksRisks include, but are not limited to: failure of DURAVYU in clinical trials, failure to obtain regulatory approval, failure to achieve commercial success due to market size, penetration rate, and/or competition, and potential dilution risk.
EyePoint Pharmaceuticals News
EYPT FAQ
What was Eyepoint Pharma’s price range in the past 12 months?
Eyepoint Pharma lowest stock price was $3.91 and its highest was $14.42 in the past 12 months.
What is Eyepoint Pharma’s market cap?
Eyepoint Pharma’s market cap is $920.18M.
When is Eyepoint Pharma’s upcoming earnings report date?
Eyepoint Pharma’s upcoming earnings report date is Oct 29, 2025 which is in 42 days.
How were Eyepoint Pharma’s earnings last quarter?
Eyepoint Pharma released its earnings results on Aug 06, 2025. The company reported -$0.85 earnings per share for the quarter, missing the consensus estimate of -$0.823 by -$0.027.
Is Eyepoint Pharma overvalued?
According to Wall Street analysts Eyepoint Pharma’s price is currently Undervalued.
Does Eyepoint Pharma pay dividends?
Eyepoint Pharma does not currently pay dividends.
What is Eyepoint Pharma’s EPS estimate?
Eyepoint Pharma’s EPS estimate is -0.77.
How many shares outstanding does Eyepoint Pharma have?
Eyepoint Pharma has 68,927,420 shares outstanding.
What happened to Eyepoint Pharma’s price movement after its last earnings report?
Eyepoint Pharma reported an EPS of -$0.85 in its last earnings report, missing expectations of -$0.823. Following the earnings report the stock price went down -2.847%.
Which hedge fund is a major shareholder of Eyepoint Pharma?
Currently, no hedge funds are holding shares in EYPT
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (147.19% Upside)
$33.00 (147.19% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 70%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 4.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.1%
Last 30 Days ▲ 3.8%
Last 30 Days ▲ 3.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
50.33%
12-Months-Change
Fundamentals
Return on Equity
-73.95%
Trailing 12-Months
Asset Growth
-7.12%
Trailing 12-Months
Company Description
Eyepoint Pharma
EyePoint Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing innovative therapies for eye diseases. The company specializes in sustained-release drug delivery systems to treat chronic ocular conditions, particularly in the areas of retinal diseases, glaucoma, and ocular inflammation. EyePoint's core products include Yutiq, an implant for the treatment of non-infectious uveitis, and Dextenza, a dissolvable insert for the treatment of post-surgical pain and inflammation.
EYPT Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
EyePoint announced significant progress in clinical trials and financial stability, highlighted by the rapid Phase III enrollment for DURAVYU and a strong cash position. However, the company also faced challenges with decreased revenue, increased operating expenses, and a higher net loss. The sentiment of the call reflects optimism about future milestones and the potential market position, but acknowledges the current financial strains due to increased investments in clinical trials.View all EYPT earnings summariesEYPT Stock 12 Month Forecast
Average Price Target
$33.00
▲(147.19% Upside)
Technical Analysis
Urogen Pharma
―
Meiragtx Holdings
―
Stoke Therapeutics
―
Tango Therapeutics
―
Pharming Group
―
Ownership Overview
0.89% Insiders
19.83% Mutual Funds
49.48% Other Institutional Investors
19.55% Public Companies and
Individual Investors